Phospho-Sulindac (OXT-328) Combined with Difluoromethylornithine Prevents Colon Cancer in Mice

@article{Mackenzie2011PhosphoSulindacC,
  title={Phospho-Sulindac (OXT-328) Combined with Difluoromethylornithine Prevents Colon Cancer in Mice},
  author={Gerardo G. Mackenzie and Nengtai Ouyang and Gang Xie and Kvetoslava Vranková and Liqun Huang and Yu Sun and Despina Komninou and Levy Kopelovich and Basil Rigas},
  journal={Cancer Prevention Research},
  year={2011},
  volume={4},
  pages={1052 - 1060}
}
The nonsteroidal anti-inflammatory drug (NSAID) sulindac and the ornithine decarboxylase (ODC) antagonist difluoromethylornithine (DFMO), individually and together, are effective inhibitors of colon carcinogenesis. However, chronic use of sulindac is associated with significant side effects. We evaluated the chemopreventive efficacy of phospho-sulindac (P-S, OXT-328), an apparently safe derivative of sulindac, together with DFMO, in HT-29 human colon cancer xenografts. Nude mice were divided… 

Tables from this paper

The anticancer effect of phospho-tyrosol-indomethacin (MPI-621), a novel phosphoderivative of indomethacin: in vitro and in vivo studies.
We have synthesized a novel derivative of indomethacin, phospho-tyrosol-indomethacin (PTI; MPI-621), and evaluated its anticancer efficacy in vitro and in vivo. PTI inhibited the growth of human
Aerosol Administration of Phospho-Sulindac Inhibits Lung Tumorigenesis
TLDR
It is found that administration by inhalation delivered high levels of phospho-sulindac to the lungs and minimized its hydrolysis to less active metabolites and was highly effective in inhibiting lung tumorigenesis and significantly improved the survival of mice bearing orthotopic A549 xenografts.
Chemotherapeutic properties of phospho-nonsteroidal anti-inflammatory drugs, a new class of anticancer compounds.
TLDR
The findings show the strong anticancer efficacy and promising safety of phospho-NSAIDs in preclinical models of breast, colon, and pancreatic cancer, suggesting further evaluation as anticancer agents.
Therapeutics , Targets , and Chemical Biology ChemotherapeuticPropertiesofPhospho-Nonsteroidal Anti-In fl ammatory Drugs , a New Class of Anticancer Compounds
TLDR
The findings show the strong anticancer efficacy and promising safety of phospho-NSAIDs in preclinical models of breast, colon, and pancreatic cancer, suggesting further evaluation as anticancer agents.
Difluoromethylornithine in cancer: new advances.
TLDR
The current knowledge of the anticancer and chemopreventive properties of DFMO is summarized and the status of clinical trials is assessed.
Phospho-Sulindac (OXT-328) Inhibits the Growth of Human Lung Cancer Xenografts in Mice: Enhanced Efficacy and Mitochondria Targeting by its Formulation in Solid Lipid Nanoparticles
TLDR
The results show that SLN-PS is efficacious in suppressing the growth of lung cancer and merits further evaluation, suggesting that it specifically induced oxidative stress in tumors.
Curcumin enhances the lung cancer chemopreventive efficacy of phospho-sulindac by improving its pharmacokinetics
TLDR
Results show that curcumin substantially improves the pharmacokinetics of PS leading to synergistic inhibition of the growth of human lung cancer xenografts, representing a promising drug combination.
The novel agent phospho-glycerol-ibuprofen-amide (MDC-330) inhibits glioblastoma growth in mice: an effect mediated by cyclin D1.
TLDR
Phospho-glycerol-ibuprofen-amide displays strong efficacy against GBM, crosses the blood-brain barrier when properly formulated, reaching the target tissue, and establishes cyclin D1 as an important molecular target.
...
...

References

SHOWING 1-10 OF 30 REFERENCES
Phospho-sulindac (OXT-328), a novel sulindac derivative, is safe and effective in colon cancer prevention in mice.
BACKGROUND & AIMS Nonsteroidal anti-inflammatory drugs (NSAIDs) are effective cancer chemopreventive agents. However, chronic administration of NSAIDs is associated with significant side effects,
The novel phenylester anticancer compounds: Study of a derivative of aspirin (phoshoaspirin).
TLDR
It is concluded that phosphoaspirin is a promising agent for the control of cancer that deserves further evaluation.
Inhibition of human ornithine decarboxylase activity by enantiomers of difluoromethylornithine.
TLDR
It is suggested that both enantiomers of DFMO irreversibly inactivate ODC and this inactivation occurs by a common mechanism, similar to that of the alpha-substituent of the inhibitor.
A Novel Sulindac Derivative That Does Not Inhibit Cyclooxygenases but Potently Inhibits Colon Tumor Cell Growth and Induces Apoptosis with Antitumor Activity
TLDR
Results indicate that SSA has potential safety and efficacy advantages for colon cancer chemoprevention as well as utility for treating malignant disease if combined with chemotherapy.
Rationale for, and design of, a clinical trial targeting polyamine metabolism for colon cancer chemoprevention
TLDR
Preclinical studies provided the rationale for colon cancer prevention trials in humans and served as a vanguard for a randomized, placebo-controlled prospective Phase III trial of the combination of DFMO and sulindac with the primary study endpoint the prevention of colon polyps.
Difluoromethylornithine Plus Sulindac for the Prevention of Sporadic Colorectal Adenomas: A Randomized Placebo-Controlled, Double-Blind Trial
TLDR
Recurrent adenomatous polyps can be markedly reduced by a combination of low oral doses of DFMO and sulindac and with few side effects.
In vivo enhancement of herpes simplex virus thymidine kinase/ganciclovir cancer gene therapy with polyamine biosynthesis inhibition
TLDR
The data here confirms that a novel combination of 2 clinically relevant treatment modalities, polyamine deprivation and HSV‐TK/GCV suicide gene therapy, can be used synergistically in vivo.
Levels of rectal mucosal polyamines and prostaglandin E2 predict ability of DFMO and sulindac to prevent colorectal adenoma.
TLDR
A combination of DFMO and sulindac significantly suppressed production of rectal mucosal polyamines but not PGE2, and baseline biomarker levels modified the effect of DF MO/sulindac for CRA prevention.
NO-donating aspirin isomers downregulate peroxisome proliferator-activated receptor (PPAR)delta expression in APC(min/+) mice proportionally to their tumor inhibitory effect: Implications for the role of PPARdelta in carcinogenesis.
TLDR
The data suggest that NO-ASA suppresses intestinal tumorigenesis possibly in part through its inhibitory effect on PPARdelta, the expression of which may contribute to intestinal carcinogenesis.
The thioredoxin system mediates redox-induced cell death in human colon cancer cells: implications for the mechanism of action of anticancer agents.
TLDR
These findings indicate that the Trx system mediates to a large extent redox-induced cell death in response to anticancer agents and deserves further assessment as a candidate mechanism for the pharmacologic control of cancer.
...
...